In Germany, carriers of pathogenic variants in ATM, BRCA1, BRCA2, BARD1, BRIP1, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, and TP53 are eligible for the intensified breast cancer surveillance (IBCS) program, which includes annual breast MRI as a core component [1]. This evidence concerns the gene RAD51C and breast carcinoma.